OncoDaily IO· @OncoDailyIO · X·· 14 小时前评分70
正文 · 原文
🧬 Phase III INTerpath-001: Adjuvant intismeran + pembrolizumab improved RFS vs pembrolizumab + placebo in resected stage IIB–IV melanoma.
24-month RFS: 82.2% vs 70.0%
HR 0.58; P <0.001
DMFS also improved; OS not yet reported.
https://oncodaily.com/oncolibrary/immune-oncology/interpath-001-2
#ESMO2026 #OncoDaily #INTerpath001
5 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：OncoDaily IO · x.com